Solid Tumor Expanded Panel
Also known as: Cancer Genomics, NGS, Tumor Profiling, Large Gene Panel, 500
Use
This next-generation sequencing panel of 523 genes provides personalized genomic analysis of a patient’s tumor to support precision oncology, including detection of single nucleotide variants, small insertions/deletions, copy‑number alterations, and translocations. It additionally assesses microsatellite instability (MSI) and tumor mutation burden (TMB), facilitating evaluation of eligibility for immune checkpoint inhibitors and aiding treatment selection, prognosis, and clinical trial planning. Any significant findings are annotated per AMP guidelines and reviewed by a Quest pathologist for physician reporting.
Special Instructions
Not provided.
Limitations
The test requires sufficient tumor content: preferred ≥20% tumor content across ≥200 mm² of tissue; minimum ≥10% tumor in ≥10 mm². Samples below these thresholds are rejected. Frozen tissue is unacceptable. It may not detect variants outside the 523‑gene content and is dependent on sample quality and tumor content.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
FFPE tissue block
Collection Instructions
Submit FFPE tissue block with a pathology report.
Storage Instructions
Room temperature
Causes for Rejection
Sample with <10% tumor content or less than minimal requirements
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 5 years |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant